High drug prices pose challenges in cancer treatment

A report in the journal Blood finds 11 of 12 FDA-approved drugs for cancer cost more than $100,000 annually, making it difficult for patients to obtain treatment for conditions such as chronic myeloid leukemia. It's part of a broader trend of high-cost treatments, researchers noted, reporting that the mean monthly cost of cancer drugs overall has increased from $5,000 to more than $10,000 in the past decade. More than 100 of the world's leading cancer specialists urged drug companies to address the issue, arguing that the prices are unsustainable. "Advocating for lower drug prices is a necessity to save the lives of patients," they wrote.

View Full Article in:

New York Times (tiered subscription model), The · U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID